Watch CGON. Know when insiders buy.
One email the day a filing lands. Free.
CGON
CG Oncology, Inc.
71.96
−1.44 −1.96%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
63
WATCH · shorts 63
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.4BP/E —DIV YIELD —FCF YIELD -2.81%REV TTM —NET INCOME −$224.4MNET CASH $16.6M52W 33.16 – 80.68SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$86.4M | −$79.1M | — | -0.90 | −$46.4M | $468K | −$46.9M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$66.4M | −$60.2M | — | -0.71 | −$56.9M | $304K | −$57.2M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$48.7M | −$41.3M | — | -0.51 | −$36.2M | $7K | −$36.2M | Feb 27 |
| Q3 2025 · Sep 30 | — | — | — | −$51.1M | −$43.8M | — | -0.57 | −$38.9M | $97K | −$39M | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$48.7M | −$41.4M | — | -0.54 | −$28M | $14K | −$28M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$42.2M | −$34.5M | — | -0.45 | −$29.3M | $16K | −$29.3M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$38M | −$31.8M | — | -0.48 | −$20.7M | $209K | −$20.9M | Feb 27 |
| Q3 2024 · Sep 30 | — | — | — | −$28.3M | −$20.4M | — | -0.30 | −$15.9M | −$1K | −$15.9M | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$25.9M | −$18.9M | — | -0.28 | −$16.1M | $14K | −$16.1M | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$22.5M | −$16.9M | — | -0.36 | −$26M | $12K | −$26M | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$19.4M | −$16.6M | — | -4.47 | −$14.6M | — | — | Feb 27 |
| Q3 2023 · Sep 30 | — | — | — | −$14M | −$11.8M | — | -4.00 | −$12.3M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$190.8M | −$161M | — | -2.08 | −$132.3M | $134K | −$132.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$114.7M | −$88M | — | -1.41 | −$78.7M | $234K | −$78.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$55.4M | −$48.6M | — | -15.65 | −$45.7M | — | — | — | — |
Every number comes from CG Oncology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.